Overview
NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults. Blueprint Medicines will not be launching the technology in the UK and has confirmed it will withdraw its submission.
Last reviewed: 29 September 2021
Next review: We will review this decision if the company decides to make a submission.